Cargando…

396. Clinical Characterization of Long COVID in Mexico

BACKGROUND: Long COVID is defined as the persistence of symptoms after 4 weeks of an acute picture. There is talk of 65 million people affected in the world. In Mexico there are no statistics or studies that explore this entity in the population. METHODS: A descriptive, cross-sectional, and prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Carpio-Orantes, Luis, García-Mendez, Sergio, Sánchez-Díaz, Jesús Salvador, Aguilar-Silva, Andrés, Martínez-Rojas, Manuel, Jiménez-Flores, Oscar Rodrigo, Villalobos-López, Luis Roberto, González-Arce, América Alejandrina, González-Medel, Karem Samantha, Domínguez-Cámara, Rubén, Munguía-Sereno, Alvaro Efrén, Zamora-Vázquez, Violeta Rosalia, Vázquez-Manzano, Quiahuitzin Elizabeth, Ortíz-Pérez, Diego, Hernández-Martínez, Semiramis Itzel, Hernández-Hernández, Sara Nohemí, Solís-Sánchez, Ishar, Fonseca-Pouchoulen, Victor Alejandro, Montano-Montiel, Laura Guadalupe, Reich-Sierra, Reynaldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677685/
http://dx.doi.org/10.1093/ofid/ofad500.466
_version_ 1785150188584697856
author Del Carpio-Orantes, Luis
García-Mendez, Sergio
Sánchez-Díaz, Jesús Salvador
Aguilar-Silva, Andrés
Martínez-Rojas, Manuel
Jiménez-Flores, Oscar Rodrigo
Villalobos-López, Luis Roberto
González-Arce, América Alejandrina
González-Medel, Karem Samantha
Domínguez-Cámara, Rubén
Munguía-Sereno, Alvaro Efrén
Zamora-Vázquez, Violeta Rosalia
Vázquez-Manzano, Quiahuitzin Elizabeth
Ortíz-Pérez, Diego
Hernández-Martínez, Semiramis Itzel
Hernández-Hernández, Sara Nohemí
Solís-Sánchez, Ishar
Fonseca-Pouchoulen, Victor Alejandro
Montano-Montiel, Laura Guadalupe
Reich-Sierra, Reynaldo
author_facet Del Carpio-Orantes, Luis
García-Mendez, Sergio
Sánchez-Díaz, Jesús Salvador
Aguilar-Silva, Andrés
Martínez-Rojas, Manuel
Jiménez-Flores, Oscar Rodrigo
Villalobos-López, Luis Roberto
González-Arce, América Alejandrina
González-Medel, Karem Samantha
Domínguez-Cámara, Rubén
Munguía-Sereno, Alvaro Efrén
Zamora-Vázquez, Violeta Rosalia
Vázquez-Manzano, Quiahuitzin Elizabeth
Ortíz-Pérez, Diego
Hernández-Martínez, Semiramis Itzel
Hernández-Hernández, Sara Nohemí
Solís-Sánchez, Ishar
Fonseca-Pouchoulen, Victor Alejandro
Montano-Montiel, Laura Guadalupe
Reich-Sierra, Reynaldo
author_sort Del Carpio-Orantes, Luis
collection PubMed
description BACKGROUND: Long COVID is defined as the persistence of symptoms after 4 weeks of an acute picture. There is talk of 65 million people affected in the world. In Mexico there are no statistics or studies that explore this entity in the population. METHODS: A descriptive, cross-sectional, and prospective study was carried out using an online survey, in adults who wish to participate and who are living in Mexico from January to March 2023, whose main objective is to characterize patients who present symptoms of Long COVID RESULTS: 336 participants with an average age of 41 years (range 18-79 years), the most affected gender is female (69%); Risk factors are Obesity 41%, Diabetes 16%, Hypertension 15.8%; 43.5% commented that they were healthy before COVID-19. Cases of acute COVID they have suffered, 42.3% comment that 2 previous infections, 29.5% had one and 28.3% 3 or more. 77% refer to mild COVID, 13% to severe COVID, and 10% both. Regarding vaccination, 45% have 3 or more vaccines, 36% 2 vaccines, 9% have one vaccine and 10% have not been vaccinated against COVID-19. The most prevalent symptoms are Neuropsychiatric 90%, Musculoskeletal 88%, Cardiovascular 82%, Gastrointestinal 78%, and Pulmonary 71%. The most frequent Neuropsychiatric symptoms: fatigue 76%, memory disorder 72%, anxiety 65%; Musculoskeletal symptoms are arthralgia 71.4%, myalgia 40%, arthritis 28%. Cardiovascular symptoms are palpitations 58%, tachycardia 38%, precordial pain 27%. Gastrointestinal symptoms are diarrhea 43%, abdominal pain 41%, Colitis 26%. Pulmonary symptoms are chronic cough 40%, persistent expectoration 29%, dyspnea 23%. Other symptoms are alopecia 53.3%, chronic dermatitis 38%, frequent infections after COVID-19 20%, menstrual disorders 17%, thyroid disease 12%, development of autoimmune diseases 9.5%, sexual dysfunction 9%, COVID tests persistently positive 6%, thrombotic events 3.6% (cerebral 0.9%, pulmonary thromboembolism 0.6%, myocardial infarction 0.3%), myocarditis 3.3%, chronic renal failure 2.4% and cancer 1.8%. [Figure: see text] [Figure: see text] CONCLUSION: It is important to characterize this population since it has particularities that make it susceptible to this new entity and the creation of clinical guidelines in the country should be encouraged to begin limiting sequelae. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677685
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106776852023-11-27 396. Clinical Characterization of Long COVID in Mexico Del Carpio-Orantes, Luis García-Mendez, Sergio Sánchez-Díaz, Jesús Salvador Aguilar-Silva, Andrés Martínez-Rojas, Manuel Jiménez-Flores, Oscar Rodrigo Villalobos-López, Luis Roberto González-Arce, América Alejandrina González-Medel, Karem Samantha Domínguez-Cámara, Rubén Munguía-Sereno, Alvaro Efrén Zamora-Vázquez, Violeta Rosalia Vázquez-Manzano, Quiahuitzin Elizabeth Ortíz-Pérez, Diego Hernández-Martínez, Semiramis Itzel Hernández-Hernández, Sara Nohemí Solís-Sánchez, Ishar Fonseca-Pouchoulen, Victor Alejandro Montano-Montiel, Laura Guadalupe Reich-Sierra, Reynaldo Open Forum Infect Dis Abstract BACKGROUND: Long COVID is defined as the persistence of symptoms after 4 weeks of an acute picture. There is talk of 65 million people affected in the world. In Mexico there are no statistics or studies that explore this entity in the population. METHODS: A descriptive, cross-sectional, and prospective study was carried out using an online survey, in adults who wish to participate and who are living in Mexico from January to March 2023, whose main objective is to characterize patients who present symptoms of Long COVID RESULTS: 336 participants with an average age of 41 years (range 18-79 years), the most affected gender is female (69%); Risk factors are Obesity 41%, Diabetes 16%, Hypertension 15.8%; 43.5% commented that they were healthy before COVID-19. Cases of acute COVID they have suffered, 42.3% comment that 2 previous infections, 29.5% had one and 28.3% 3 or more. 77% refer to mild COVID, 13% to severe COVID, and 10% both. Regarding vaccination, 45% have 3 or more vaccines, 36% 2 vaccines, 9% have one vaccine and 10% have not been vaccinated against COVID-19. The most prevalent symptoms are Neuropsychiatric 90%, Musculoskeletal 88%, Cardiovascular 82%, Gastrointestinal 78%, and Pulmonary 71%. The most frequent Neuropsychiatric symptoms: fatigue 76%, memory disorder 72%, anxiety 65%; Musculoskeletal symptoms are arthralgia 71.4%, myalgia 40%, arthritis 28%. Cardiovascular symptoms are palpitations 58%, tachycardia 38%, precordial pain 27%. Gastrointestinal symptoms are diarrhea 43%, abdominal pain 41%, Colitis 26%. Pulmonary symptoms are chronic cough 40%, persistent expectoration 29%, dyspnea 23%. Other symptoms are alopecia 53.3%, chronic dermatitis 38%, frequent infections after COVID-19 20%, menstrual disorders 17%, thyroid disease 12%, development of autoimmune diseases 9.5%, sexual dysfunction 9%, COVID tests persistently positive 6%, thrombotic events 3.6% (cerebral 0.9%, pulmonary thromboembolism 0.6%, myocardial infarction 0.3%), myocarditis 3.3%, chronic renal failure 2.4% and cancer 1.8%. [Figure: see text] [Figure: see text] CONCLUSION: It is important to characterize this population since it has particularities that make it susceptible to this new entity and the creation of clinical guidelines in the country should be encouraged to begin limiting sequelae. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677685/ http://dx.doi.org/10.1093/ofid/ofad500.466 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Del Carpio-Orantes, Luis
García-Mendez, Sergio
Sánchez-Díaz, Jesús Salvador
Aguilar-Silva, Andrés
Martínez-Rojas, Manuel
Jiménez-Flores, Oscar Rodrigo
Villalobos-López, Luis Roberto
González-Arce, América Alejandrina
González-Medel, Karem Samantha
Domínguez-Cámara, Rubén
Munguía-Sereno, Alvaro Efrén
Zamora-Vázquez, Violeta Rosalia
Vázquez-Manzano, Quiahuitzin Elizabeth
Ortíz-Pérez, Diego
Hernández-Martínez, Semiramis Itzel
Hernández-Hernández, Sara Nohemí
Solís-Sánchez, Ishar
Fonseca-Pouchoulen, Victor Alejandro
Montano-Montiel, Laura Guadalupe
Reich-Sierra, Reynaldo
396. Clinical Characterization of Long COVID in Mexico
title 396. Clinical Characterization of Long COVID in Mexico
title_full 396. Clinical Characterization of Long COVID in Mexico
title_fullStr 396. Clinical Characterization of Long COVID in Mexico
title_full_unstemmed 396. Clinical Characterization of Long COVID in Mexico
title_short 396. Clinical Characterization of Long COVID in Mexico
title_sort 396. clinical characterization of long covid in mexico
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677685/
http://dx.doi.org/10.1093/ofid/ofad500.466
work_keys_str_mv AT delcarpioorantesluis 396clinicalcharacterizationoflongcovidinmexico
AT garciamendezsergio 396clinicalcharacterizationoflongcovidinmexico
AT sanchezdiazjesussalvador 396clinicalcharacterizationoflongcovidinmexico
AT aguilarsilvaandres 396clinicalcharacterizationoflongcovidinmexico
AT martinezrojasmanuel 396clinicalcharacterizationoflongcovidinmexico
AT jimenezfloresoscarrodrigo 396clinicalcharacterizationoflongcovidinmexico
AT villaloboslopezluisroberto 396clinicalcharacterizationoflongcovidinmexico
AT gonzalezarceamericaalejandrina 396clinicalcharacterizationoflongcovidinmexico
AT gonzalezmedelkaremsamantha 396clinicalcharacterizationoflongcovidinmexico
AT dominguezcamararuben 396clinicalcharacterizationoflongcovidinmexico
AT munguiaserenoalvaroefren 396clinicalcharacterizationoflongcovidinmexico
AT zamoravazquezvioletarosalia 396clinicalcharacterizationoflongcovidinmexico
AT vazquezmanzanoquiahuitzinelizabeth 396clinicalcharacterizationoflongcovidinmexico
AT ortizperezdiego 396clinicalcharacterizationoflongcovidinmexico
AT hernandezmartinezsemiramisitzel 396clinicalcharacterizationoflongcovidinmexico
AT hernandezhernandezsaranohemi 396clinicalcharacterizationoflongcovidinmexico
AT solissanchezishar 396clinicalcharacterizationoflongcovidinmexico
AT fonsecapouchoulenvictoralejandro 396clinicalcharacterizationoflongcovidinmexico
AT montanomontiellauraguadalupe 396clinicalcharacterizationoflongcovidinmexico
AT reichsierrareynaldo 396clinicalcharacterizationoflongcovidinmexico